ArticlePloS one2025
Effects of long-term metformin intake on postoperative clinicopathological characteristics in patients with invasive lung adenocarcinoma and type 2 diabetes mellitus: A retrospective analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Old Drug, New Science: Metformin and the Future of Pharmaceutics.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective study aimed to evaluate whether long-term metformin use is associated with less aggressive clinicopathological characteristics in patients with invasive lung adenocarcinoma (LUAD) and type 2 diabetes mellitus (T2DM).
methodsWe reviewed patients with both invasive LUAD and T2DM who underwent curative lung cancer resection and lymph node dissection between January 2012 and August 2022. Patients were divided into a metformin group and a non-metformin group based on their antidiabetic treatment. Clinicopathological outcomes included tumor size, TNM stage, histologic differentiation, Ki-67 expression, and pathological subtypes. Comparisons were made using Student's t-test, Mann-Whitney U test, χ² test, or Fisher's exact test, as appropriate.
resultsA total of 130 patients were included (45 metformin users and 85 non-users), with no significant differences in baseline characteristics. The metformin group showed smaller tumors (1.78 ± 0.87 cm vs. 2.21 ± 1.28 cm; p = 0.049), fewer cases of high Ki-67 expression (>15%) (35.6% vs. 62.3%; p = 0.004), and no lymph node metastasis (0% vs. 15.3%; p = 0.022). Additionally, patients on metformin had better differentiation (p = 0.039) and earlier TNM stages (p = 0.03).
conclusionLong-term metformin use in diabetic patients with invasive LUAD was associated with more favorable clinicopathological features, including smaller tumor size, lower proliferative index, and absence of nodal metastasis. These findings support a potential anti-tumor role of metformin in lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.